inhalation administration

Summary

Summary: The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.

Top Publications

  1. ncbi Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
  2. ncbi The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol
    Harold S Nelson
    National Jewish Medical and Research Center, Denver, CO, USA
    Chest 129:15-26. 2006
  3. ncbi Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia
    Pierre Ernst
    Pharmacoepidemiology Research Unit, Department of Medicine, McGill University Health Centre, and Division of Clinical Epidemiology, Ross 4 29, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, PQ, Quebec, H3A 1A1 Canada
    Am J Respir Crit Care Med 176:162-6. 2007
  4. ncbi Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Eur Respir J 26:214-22. 2005
  5. ncbi Hospitalizations and mortality in the Lung Health Study
    Nicholas R Anthonisen
    University of Manitoba, Winnipeg, Manitoba, Canada
    Am J Respir Crit Care Med 166:333-9. 2002
  6. ncbi Large porous particles for pulmonary drug delivery
    D A Edwards
    Department of Chemical Engineering, Pennsylvania State University, 204 Fenske Laboratory, University Park, PA 16802, USA
    Science 276:1868-71. 1997
  7. pmc Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
    G C Donaldson
    Academic Unit of Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, UK
    Thorax 57:847-52. 2002
  8. ncbi Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease
    D E O'Donnell
    Respiratory Investigation Unit, Dept of Medicine, Queen s University, Kingston, Canada
    Eur Respir J 24:86-94. 2004
  9. ncbi The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study
    Keith L Hattotuwa
    Lung Pathology Unit, Imperial College School of Medicine at the Royal Brompton Hospital, London, United Kingdom
    Am J Respir Crit Care Med 165:1592-6. 2002
  10. ncbi Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease
    Neil C Barnes
    Department of Respiratory Medicine, London Chest Hospital, London, UK
    Am J Respir Crit Care Med 173:736-43. 2006

Detail Information

Publications307 found, 100 shown here

  1. ncbi Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
    ..Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown...
  2. ncbi The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol
    Harold S Nelson
    National Jewish Medical and Research Center, Denver, CO, USA
    Chest 129:15-26. 2006
    ..To compare the safety of salmeterol xinafoate or placebo added to usual asthma care...
  3. ncbi Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia
    Pierre Ernst
    Pharmacoepidemiology Research Unit, Department of Medicine, McGill University Health Centre, and Division of Clinical Epidemiology, Ross 4 29, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, PQ, Quebec, H3A 1A1 Canada
    Am J Respir Crit Care Med 176:162-6. 2007
    ..Inhaled corticosteroids are commonly prescribed to patients with chronic obstructive pulmonary disease (COPD)...
  4. ncbi Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Eur Respir J 26:214-22. 2005
    ..i.d. A combination of both drugs q.d. was most effective and provided an additive effect throughout the 24-h dosing interval...
  5. ncbi Hospitalizations and mortality in the Lung Health Study
    Nicholas R Anthonisen
    University of Manitoba, Winnipeg, Manitoba, Canada
    Am J Respir Crit Care Med 166:333-9. 2002
    ..When all participants were considered and smoking status considered as a time-dependent covariate, smoking cessation was associated with significant reductions in fatal or nonfatal cardiovascular disease and coronary artery disease...
  6. ncbi Large porous particles for pulmonary drug delivery
    D A Edwards
    Department of Chemical Engineering, Pennsylvania State University, 204 Fenske Laboratory, University Park, PA 16802, USA
    Science 276:1868-71. 1997
    ..High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 micrometers) approximately 10 times that of conventional inhaled therapeutic particles...
  7. pmc Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
    G C Donaldson
    Academic Unit of Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, UK
    Thorax 57:847-52. 2002
    ..The aim of this study was to investigate whether these are related...
  8. ncbi Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease
    D E O'Donnell
    Respiratory Investigation Unit, Dept of Medicine, Queen s University, Kingston, Canada
    Eur Respir J 24:86-94. 2004
    ..Bronchodilator-induced lung deflation reduced mechanical restriction, increased ventilatory capacity and decreased respiratory discomfort, thereby increasing exercise endurance...
  9. ncbi The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study
    Keith L Hattotuwa
    Lung Pathology Unit, Imperial College School of Medicine at the Royal Brompton Hospital, London, United Kingdom
    Am J Respir Crit Care Med 165:1592-6. 2002
    ..The data indicate that inhaled fluticasone does affect selected aspects of airway inflammation in COPD, and this may explain, in part, the decrease in exacerbations seen in long-term studies with fluticasone propionate...
  10. ncbi Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease
    Neil C Barnes
    Department of Respiratory Medicine, London Chest Hospital, London, UK
    Am J Respir Crit Care Med 173:736-43. 2006
    ..No currently available treatment is reported to reduce the exaggerated airway wall inflammation of chronic obstructive pulmonary disease...
  11. pmc Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation
    B N Lambrecht
    Department of Pulmonary Medicine, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Clin Invest 106:551-9. 2000
    ..These data demonstrate that DCs in the airways induce sensitization to inhaled antigen and that molecules expressed on the surface of these cells are critical for the development of Th2-dependent airway eosinophilia...
  12. pmc Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
    Robert F Lemanske
    University of Wisconsin School of Medicine and Public Health, Madison, USA
    N Engl J Med 362:975-85. 2010
    ..For children who have uncontrolled asthma despite the use of low-dose inhaled corticosteroids (ICS), evidence to guide step-up therapy is lacking...
  13. ncbi Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD
    Min J Joo
    Section of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Respir Med 104:246-52. 2010
    ..Little is known of this risk in newly diagnosed COPD patients. The objective of this study was to determine if the use of ICS among newly diagnosed COPD patients is associated with an increased risk of pneumonia hospitalizations...
  14. pmc Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma
    S Suissa
    Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University Health Centre, McGill University, Montreal, Canada
    Thorax 57:880-4. 2002
    ..Inhaled corticosteroids are effective at preventing asthma morbidity and mortality. Most studies, however, have focused on short term effects, raising uncertainty about their effectiveness in the long term...
  15. ncbi The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, A Cardarelli Hospital, Via del Parco Margherita 24, Naples 80121, Italy
    Pulm Pharmacol Ther 17:35-9. 2004
    ..Since tiotropium ensures prolonged bronchodilation, whereas formoterol adds fast onset and a greater peak effect, the two drugs appear complementary...
  16. ncbi Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size
    Omar S Usmani
    Department of Thoracic Medicine, Airways Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Am J Respir Crit Care Med 172:1497-504. 2005
    ..Aerosol particle size influences the extent, distribution, and site of inhaled drug deposition within the airways...
  17. ncbi Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD
    M Cazzola
    Division of Pneumology and Allergology and Unit of Respiratory Clinical Pharmacology, A Cardarelli Hospital, Naples, Italy
    Pulm Pharmacol Ther 14:41-5. 2001
    ..Again, there was no significant difference (P= 0.817) between the four active treatments. Formoterol Turbuhaler 12 microg and 24 microg caused bronchodilation as rapidly as salbutamol 400 microg and 800 microg given via pMDI...
  18. ncbi Inflammatory changes, recovery and recurrence at COPD exacerbation
    W R Perera
    Academic Unit of Respiratory Medicine, Royal Free and University College Medical School, Rowland Hill Street, Hampstead, London, NW3 2PF, UK
    Eur Respir J 29:527-34. 2007
    ..A high serum C-reactive protein concentration 14 days after an index exacerbation may be used as a predictor of recurrent exacerbations within 50 days...
  19. pmc Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis
    S Holt
    Wellington Asthma Research Group, Wellington School of Medicine, PO Box 7343, Wellington, New Zealand
    BMJ 323:253-6. 2001
    ..However, these findings were limited by the lack of data on individual patients and by the paucity of dose-response studies that included doses of >500 microg/day...
  20. ncbi Budesonide and the risk of pneumonia: a meta-analysis of individual patient data
    Don D Sin
    Providence Heart and Lung Institute, St Paul s Hospital iCAPTURE Centre, and Department of Medicine Division of Respirology, University of British Columbia, Vancouver, BC, Canada
    Lancet 374:712-9. 2009
    ..We aimed to establish the effects of inhaled budesonide on the risk of pneumonia in such patients...
  21. ncbi Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler
    David E Geller
    The Nemours Children s Clinic, Orlando, Florida 32806, USA
    Respir Care 50:1313-21; discussion 1321-2. 2005
    ..Clinicians should also have a rudimentary understanding of aerosol principles in order to be able to teach appropriate use of aerosol devices to their patients...
  22. ncbi A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
    M E Hodson
    Royal Brompton and Harefield NHS Trust, London, UK
    Eur Respir J 20:658-64. 2002
    ..Both treatments reduced the bacterial load...
  23. pmc Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
    E F M Wouters
    Department of Respiratory Medicine, University Hospital Maastricht, The Netherlands
    Thorax 60:480-7. 2005
    ..Combined treatment with ICS and long acting beta2 agonists (LABA) may provide benefit to the stability of COPD, but it is unknown if withdrawal of ICS will result in disease deterioration...
  24. ncbi Prescription bias and factors associated with improper use of inhalers
    Piersante Sestini
    Department of Clinical Medicine and Immunological Sciences, Section of Respiratory Diseases, University of Siena, Siena, Italy
    J Aerosol Med 19:127-36. 2006
    ..The prescription of newer DPIs may be subjected to gender, socio-economic, and instruction bias. The simple change of device from the pMDI to the newer DPIs is not associated with improved inhalation technique...
  25. ncbi The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Respir Med 103:22-9. 2009
    ..The Respimat Soft Mist Inhaler (SMI), a novel, propellant-free inhaler, has been developed and proposed as an alternative delivery device for use with tiotropium...
  26. ncbi Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions
    Hiromitsu Yamamoto
    Gifu Pharmaceutical University, 5 6 1, Mitahora higashi Gifu 502 8585, Japan
    J Control Release 102:373-81. 2005
    ..4000)>FD-21 (Mw. 21,000)>FD70 (Mw. 70,000), which corresponded to the molecular weights ([Mw.] given in parentheses). The absorption-enhancing effect may have been caused by opening the intercellular tight junctions...
  27. ncbi Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles
    Shirzad Azarmi
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alta, Canada T6G 2N8
    Int J Pharm 319:155-61. 2006
    ..The cell uptake of free DOX and DOX delivered by nanoparticles was confirmed using confocal laser scanning microscopy. This study supports the approach of lung cancer treatment using nanoparticles in dry powder aerosol form...
  28. ncbi The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD
    Jin ping Zheng
    Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120, People s Republic of China
    Chest 132:1756-63. 2007
    ....
  29. ncbi Characteristics of U.S. waterpipe users: a preliminary report
    Kenneth D Ward
    Department of Health and Sport Sciences, University of Memphis, Memphis, TN 38152, USA
    Nicotine Tob Res 9:1339-46. 2007
    ..Educational efforts are needed to increase awareness of the potential hazards of this increasingly popular form of tobacco use...
  30. ncbi Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats
    Gunter Oberdorster
    University of Rochester, Department of Environmental Medicine, Rochester, New York 14642, USA
    J Toxicol Environ Health A 65:1531-43. 2002
    ..Such translocation to blood and extrapulmonary tissues may well be different between ultrafine carbon and other insoluble (metal) ultrafine particles...
  31. ncbi Nanoparticles for drug delivery to the lungs
    Jean C Sung
    Harvard School of Engineering and Applied Sciences, 40 Oxford Street, ESL 406, Cambridge, MA 02138, USA
    Trends Biotechnol 25:563-70. 2007
    ..This review covers the development of nanoparticle formulations for pulmonary delivery as both individual nanoparticles and encapsulated within carrier particles...
  32. ncbi Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events
    Eric Bateman
    Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Ann Intern Med 149:33-42. 2008
    ..Recent analyses have suggested an increased risk for serious asthma-related adverse events in patients receiving long-acting beta-agonists...
  33. ncbi Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial
    Shawn D Aaron
    The Ottawa Health Research Institute and University of Ottawa, Ottawa, Ontario, Canada
    Ann Intern Med 146:545-55. 2007
    ..Treatment of moderate or severe chronic obstructive pulmonary disease (COPD) with combinations of inhaled corticosteroids, long-acting beta-agonists, and long-acting anticholinergic bronchodilators is common but unstudied...
  34. ncbi Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma
    Colin R Dormuth
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Ther 28:964-78; discussion 962-3. 2006
    ..Evaluations of drug cost-sharing policies within the same population are needed for a fair comparison of different options...
  35. ncbi Cardiovascular events associated with ipratropium bromide in COPD
    Sarika S Ogale
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
    Chest 137:13-9. 2010
    ..We sought to examine the association between ipratropium bromide use and the risk of cardiovascular events (CVEs)...
  36. ncbi Mucus clearance and lung function in cystic fibrosis with hypertonic saline
    Scott H Donaldson
    University of North Carolina at Chapel Hill Cystic Fibrosis Research and Treatment Center, Chapel Hill 27599, USA
    N Engl J Med 354:241-50. 2006
    ..Through osmotic forces, hypertonic saline may increase the volume of airway surface liquid, restore mucus clearance, and improve lung function...
  37. ncbi The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team
    G K Crompton
    Respiratory Unit, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, Scotland, UK
    Respir Med 100:1479-94. 2006
    ..There is also a need for standardisation of prescribing practices throughout Europe. Regular checking of inhalation technique by prescribers is crucial as correct inhalation is one of the keystones of successful asthma management...
  38. ncbi Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience
    C R Hansen
    Department of Pediatrics, 5003, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
    J Cyst Fibros 7:523-30. 2008
    ..Since 1989, CF-patients intermittently colonized with Pseudomonas aeruginosa have been treated with inhaled colistin and oral ciprofloxacin in the Copenhagen CF-centre. The study evaluates 15 years results of this treatment...
  39. ncbi Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction
    C Frostell
    Department of Anesthesia, Harvard Medical School, Massachusetts General Hospital, Boston
    Circulation 83:2038-47. 1991
    ..Conclusions. Low dose inhaled NO (5-80 ppm) is a selective pulmonary vasodilator reversing both hypoxia- and thromboxane-induced pulmonary hypertension in the awake lamb [corrected]...
  40. ncbi Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial
    Thérèse S Lapperre
    Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
    Ann Intern Med 151:517-27. 2009
    ..Inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) are used to treat moderate to severe chronic obstructive pulmonary disease (COPD)...
  41. ncbi Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease
    D E O'Donnell
    Respiratory Investigation Unit, Departments of Medicine and Community Health and Epidemiology, Queen s University, Kingston, Ontario, Canada
    Am J Respir Crit Care Med 160:542-9. 1999
    ..IC should be used in conjunction with FEV(1) when evaluating therapeutic responses in COPD...
  42. ncbi Inhaled iloprost for severe pulmonary hypertension
    Horst Olschewski
    Department of Internal Medicine II, University Clinic, Giessen, Germany
    N Engl J Med 347:322-9. 2002
    ..Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and exercise capacity in patients with pulmonary hypertension...
  43. ncbi Nitrogen dioxide promotes allergic sensitization to inhaled antigen
    Mieke Bevelander
    Vermont Lung Center, University of Vermont, Burlington, VT 05405, USA
    J Immunol 179:3680-8. 2007
    ..These findings offer a mechanism whereby allergen sensitization and asthma may result under conditions of high ambient or endogenous NO2 levels...
  44. ncbi Chronically inhaled salmeterol improves pulmonary function in heart failure
    Tien M H Ng
    Department of Pharmacy Practice, University of Utah Health Sciences Center, Salt Lake City, UT, USA
    J Cardiovasc Pharmacol 40:140-5. 2002
    ..The plasma half-life of salmeterol may be prolonged in heart failure patients, thus leading to accumulation at steady-state...
  45. ncbi Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, Cardarelli Hospital, Naples, Italy
    Drugs 65:1595-610. 2005
    ..Therefore, beta(2)-agonists must always be used with caution in patients with cardiopathies because these agents may precipitate the concomitant cardiac disease...
  46. pmc Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma
    G W Chalmers
    Departments of Respiratory Medicine and Immunology, Western Infirmary, Glasgow G11 6NT, UK
    Thorax 57:226-30. 2002
    ..A study was undertaken to investigate the effect of active cigarette smoking on responses to treatment with inhaled corticosteroids in patients with mild asthma...
  47. ncbi Potential adverse effects of the inhaled corticosteroids
    H William Kelly
    Department of Pediatrics, University of New Mexico Children s Hospital, ACC Building 3rd Floor, 2211 Lomas Boulevard NE, Albuquerque, NM 87131 5311, USA
    J Allergy Clin Immunol 112:469-78; quiz 479. 2003
    ..The data are insufficient to determine whether there is an effect on attainment of predicted adult height. The ICSs affect bone mineral density and risk of fractures in a dose-dependent fashion that appears significant at high doses...
  48. ncbi Adherence to asthma controller medication regimens
    D A Stempel
    Department of Pediatrics, Infomed Northwest and University of Washington, Bellevue, WA 98004, USA
    Respir Med 99:1263-7. 2005
    ....
  49. ncbi Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids
    J C Virchow
    Department of Pneumology, University Medical Clinic Freiburg, Germany and AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom
    Am J Respir Crit Care Med 162:578-85. 2000
    ....
  50. ncbi Salmeterol, a beta2-receptor agonist, attenuates lipopolysaccharide-induced lung inflammation in mice
    Nico A Maris
    Department of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
    Am J Physiol Lung Cell Mol Physiol 286:L1122-8. 2004
    ..These data suggest that salmeterol inhibits lipopolysaccharide-induced neutrophil recruitment to the lungs by a mechanism that possibly in part is mediated by an effect on neutrophil CD11b...
  51. ncbi Capsaicin inhalation test for identification of sensory hyperreactivity
    A Johansson
    Allergy Centre, Central Hospital, Skovde, Sweden
    Respir Med 96:731-5. 2002
    ..However, these patients have been found to be more sensitive to inhalation of capsaicin than healthy people. The aim of this study was to establish limit values with the capsaicin inhalation test in patients with SHR...
  52. ncbi Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline
    Timothy J Wilt
    Minnesota Agency for Healthcare Research and Quality Evidence based Practice Center, Minneapolis Veterans Affairs Medical Center, and University of Minnesota, Minneapolis, Minnesota 55417, USA
    Ann Intern Med 147:639-53. 2007
    ....
  53. ncbi Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction
    David H Au
    Health Services Research and Development, Northwest Center of Excellence, VA Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA 98108, USA
    Chest 123:1964-9. 2003
    ..We sought to determine if use of selective beta(2)-agonists was associated with hospitalization for heart failure and all-cause mortality...
  54. ncbi Use of carbon monoxide as a therapeutic agent: promises and challenges
    Roberta Foresti
    Vascular Biology Unit, Department of Surgical Research, Northwick Park Institute for Medical Research, HA1 3UJ, Harrow, Middlesex, UK
    Intensive Care Med 34:649-58. 2008
    ....
  55. ncbi Old age and gender influence the pharmacokinetics of inhaled manganese sulfate and manganese phosphate in rats
    David C Dorman
    CIIT Centers for Health Research, Research Triangle Park, NC 27709 2137, USA
    Toxicol Appl Pharmacol 197:113-24. 2004
    ..Data from this study should prove useful in developing dosimetry models for manganese that consider age or gender as potential sensitivity factors...
  56. ncbi Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfaction
    K Sheth
    Lafayette Allergy and Asthma Clinic, Lafayette, IN 47905, USA
    Int J Clin Pract 60:1218-24. 2006
    ..This integrated MDI counter may help patients maintain better disease control by enabling them to accurately track their medication supply...
  57. ncbi A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis
    Paul Scheinberg
    Atlanta Pulmonary Group, 5667 Peachtree Dunwoody Rd, Suite 350, Atlanta, GA 30350, USA
    Chest 127:1420-6. 2005
    ..To evaluate the efficacy and safety of tobramycin solution for inhalation (TSI) in patients with severe bronchiectasis...
  58. ncbi The immunomodulatory actions of prostaglandin E2 on allergic airway responses in the rat
    James G Martin
    Meakins Christie Laboratories, Department of Medicine, McGill University, Montreal, Quebec, Canada
    J Immunol 169:3963-9. 2002
    ..We conclude that PGE(2) is a potent anti-inflammatory agent that may act by reducing allergen-induced Th2 cell activation and cysteinyl-leukotriene synthesis in the rat...
  59. ncbi Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma
    H Derendorf
    Dept of Pharmaceutics, University of Florida, 100494 College of Pharmacy, Gainesville, FL 32610, USA
    Eur Respir J 28:1042-50. 2006
    ....
  60. ncbi A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma
    Jean Bousquet
    Service des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Centre Hospitalier Universitaire Montpellier, France
    Clin Ther 24:1-20. 2002
    ..Although inhaled corticosteroids (ICS) are commonly used in the treatment of persistent asthma, the relationship between dose and clinical response remains unclear...
  61. pmc Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update
    Sonal Singh
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Curr Opin Pulm Med 16:118-22. 2010
    ....
  62. pmc Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis
    Wen Qi Gan
    James Hogg iCAPTURE Center for Cardiovascular and Pulmonary Research, St, Paul s Hospital and the Department of Medicine Pulmonary Division, University of British Columbia, Vancouver, Canada
    BMC Pulm Med 5:3. 2005
    ..We sought to determine the effects of inhaled corticosteroids on sputum indices of inflammation in stable COPD...
  63. ncbi Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics
    Anthony J Hickey
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Campus Box 7360, 1310 Kerr Hall, Kerr Hall, Chapel Hill, North Carolina 27599 7360, USA
    J Pharm Sci 96:1282-301. 2007
    ..This is the first of two papers that discuss static and dynamic methods of characterizing dry powder inhaler formulations...
  64. ncbi Nanoparticle formulations in pulmonary drug delivery
    Mark M Bailey
    Department of Chemical and Petroleum Engineering, The University of Kansas, Lawrence, KS 66047, USA
    Med Res Rev 29:196-212. 2009
    ..Here, the benefits of nanoparticle formulations and current progress are compared in light of the practical encumbrances of producing formulations, and possible toxicological effects of these materials...
  65. ncbi Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial
    Rudolf A Baumgartner
    Sepracor Inc, Marlborough, Massachusetts 01752, USA
    Clin Ther 29:261-78. 2007
    ....
  66. ncbi Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis
    M Bradley Drummond
    Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD 21287, USA
    JAMA 300:2407-16. 2008
    ..Recent studies of inhaled corticosteroid (ICS) therapy for managing stable chronic obstructive pulmonary disease (COPD) have yielded conflicting results regarding survival and risk of adverse events...
  67. ncbi Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers
    Chet L Leach
    3M Pharmaceuticals, St Paul, MN, USA
    Chest 122:510-6. 2002
    ..To compare the lung deposition of radiolabeled hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) with chlorofluorocarbon fluticasone propionate (CFC-FP) and chlorofluorocarbon beclomethasone (CFC-BDP)...
  68. ncbi CCL7 and CXCL10 orchestrate oxidative stress-induced neutrophilic lung inflammation
    Lidia Michalec
    National Institutes of Health Asthma and Allergic Diseases Research Center and Department of Internal Medicine and Department Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX 77555, USA
    J Immunol 168:846-52. 2002
    ..These observations may have relevance in induction of neutrophilia in severe asthma...
  69. ncbi Use of exhaled nitric oxide measurements to guide treatment in chronic asthma
    Andrew D Smith
    Respiratory Research Unit, Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
    N Engl J Med 352:2163-73. 2005
    ..Measurements of the fraction of exhaled nitric oxide (FE(NO)) constitute a noninvasive marker that may be a useful alternative for the adjustment of inhaled-corticosteroid treatment...
  70. ncbi Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study
    E Bathoorn
    Dept of Pulmonology, Groningen Research Instsitute for Asthma and COPD, The Netherlands
    Eur Respir J 30:1131-7. 2007
    ..Further studies need to confirm the safety and efficacy in inflammatory lung diseases...
  71. ncbi Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease
    Todd A Lee
    Center for Management of Complex Chronic Care, Edward Hines Jr VA Hospital, Hines, Illinois, USA
    Arch Intern Med 169:1403-10. 2009
    ..Our objective was to evaluate the comparative effectiveness of regimens containing tiotropium bromide vs other medication regimens for chronic obstructive pulmonary disease (COPD) in real-world clinical settings...
  72. pmc Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
    D B Price
    Department of General Practice and Primary Care, University of Aberdeen, Foresterhill Health Centre, Westburn Road, Aberdeen AB25 2AY, Scotland, UK
    Thorax 58:211-6. 2003
    ..This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma...
  73. ncbi Long-term inhaled corticosteroids in preschool children at high risk for asthma
    Theresa W Guilbert
    Division of Pediatric Pulmonary Medicine, Arizona Respiratory Center, University of Arizona, Tucson, AZ 85724, USA
    N Engl J Med 354:1985-97. 2006
    ..It is unknown whether inhaled corticosteroids can modify the subsequent development of asthma in preschool children at high risk for asthma...
  74. ncbi Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis
    H Olschewski
    Depatment of Internal Medicine II, Justus Liebig University, Giessen, Germany
    Am J Respir Crit Care Med 160:600-7. 1999
    ..Long-term therapy with inhaled iloprost may be life saving in decompensated right heart failure from pulmonary hypertension secondary to lung fibrosis...
  75. pmc Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma
    M J Vaquerizo
    Merck Sharp and Dohme, c Josefa Valcarcel 38, 28027 Madrid, Spain
    Thorax 58:204-10. 2003
    ..A 16 week multicentre, randomised, double blind, controlled study was undertaken to study the efficacy of adding oral montelukast, a leukotriene receptor antagonist, to a constant dose of inhaled budesonide...
  76. ncbi Inhaled corticosteroids: past lessons and future issues
    David B Allen
    Division of Endocrinology, University of Wisconsin Children s Hospital, Madison 53792 4108, USA
    J Allergy Clin Immunol 112:S1-40. 2003
    ....
  77. ncbi Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis
    B J Lipworth
    Department of Clinical Pharmacology and Therapeutics and Respiratory Medicine, Ninewells Hospital and Medical School, University of Dundee, Scotland
    Arch Intern Med 159:941-55. 1999
    ..To appraise the data on systemic adverse effects of inhaled corticosteroids...
  78. ncbi Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension
    H Wilkens
    Medizinische Klinik und Poliklinik, Innere Medizin V, Innere Medizin III, Homburg Saar, Germany
    Circulation 104:1218-22. 2001
    ..However, repetitive inhalations are required due to its short-term effects. One potential approach to prolong and increase the vasorelaxant effects of aerosolized iloprost might be to combine use with phosphodiesterase inhibitors...
  79. ncbi Short-term smoke exposure attenuates ovalbumin-induced airway inflammation in allergic mice
    Barbro N Melgert
    Department of Pathology and Laboratory Medicine, University Hospital Groningen, P O Box 30 001, 9700 RB, Groningen, The Netherlands
    Am J Respir Cell Mol Biol 30:880-5. 2004
    ..This effect of smoking may be different for long-term smoking, in which remodeling effects of smoking can be expected to interrelate with remodeling changes caused by asthmatic disease...
  80. ncbi Concomitant inhalation of cigarette smoke and aerosolized protein activates airway dendritic cells and induces allergic airway inflammation in a TLR-independent way
    Lander J Robays
    Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
    J Immunol 183:2758-66. 2009
    ..The TLR independency of this phenomenon suggests that alternative immunological adjuvants are present in cigarette smoke...
  81. ncbi Methods for therapeutic trials in COPD: lessons from the TORCH trial
    O N Keene
    GlaxoSmithKline Research and Development, Stockley Park, 1 3 Iron Bridge Road, Uxbridge, Middlesex UB11 1BU, UK
    Eur Respir J 34:1018-23. 2009
    ..No definitive conclusions can yet be drawn on whether ICS treatment has an effect on mortality...
  82. ncbi Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial
    Cynthia Rand
    Johns Hopkins School of Medicine, Baltimore, MD 21224, USA
    J Allergy Clin Immunol 119:916-23. 2007
    ..Nonadherence with asthma therapy is common and may contribute to poor clinical outcomes...
  83. ncbi Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial
    Dennis E Niewoehner
    Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA
    Ann Intern Med 143:317-26. 2005
    ..Patients with chronic obstructive pulmonary disease (COPD) frequently develop exacerbations, leading to major clinical and health resource use ramifications...
  84. ncbi Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis
    Juliet M Foster
    Department of General Practice and Primary Care, University of Aberdeen, Foresterhill AB25 2AY, Scotland
    Respir Med 100:1318-36. 2006
    ..The range and extent of inhaled corticosteroid (ICS) side effects experienced by patients in the general community are likely to be underestimated...
  85. ncbi Lung surfactant as a drug delivery system
    C Vermehren
    Department of Pharmaceutics, The Danish University of Pharmaceutical Sciences, Universitetsparken 2, DK 2100 Copenhagen, Denmark
    Int J Pharm 307:89-92. 2006
    ..This study suggests that HL10 may be a promising drug delivery system for the pulmonary delivery of amphipathic drug substances, e.g. therapeutically active acylated peptides (e.g. acylated insulin)...
  86. pmc A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management
    R Louis
    Pneumology, CHU Sart Tilman, Liege, Belgium
    Int J Clin Pract 63:1479-88. 2009
    ....
  87. ncbi Inhalation administration of all-trans-retinoic acid for treatment of elastase-induced pulmonary emphysema in Fischer 344 rats
    Thomas H March
    Lovelace Respiratory Research Institute, Albuquerque, New Mexico 87108 5127, USA
    Exp Lung Res 30:383-404. 2004
    ....
  88. ncbi Genomic analysis of the rat lung following elemental mercury vapor exposure
    Jie Liu
    Inorganic Carcinogenesis Section, NCI at NIEHS, Research Triangle Park, North Carolina 27709, USA
    Toxicol Sci 74:174-81. 2003
    ..In summary, genomic analysis revealed an array of gene alterations in response to Hg0 vapor exposure, which could be important for the development of pulmonary adaptation to Hg during Hg0 vapor inhalation...
  89. ncbi Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action
    G Celik
    Department of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Turkey
    Respiration 66:434-9. 1999
    ..In contrast to the well-known activity profile in asthma, the precise efficacy and optimum dose schedules of long-acting beta(2)-agonists in chronic obstructive pulmonary disease (COPD) are not clear...
  90. ncbi Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients
    Sabine Häussermann
    Inamed Research GmbH and Co KG, Robert Koch Allee 29, 82131 Gauting, Germany
    J Aerosol Med 20:331-41. 2007
    ..8 microm) of the HFA-Formoterol-Formulation and the slow inhalation (30 L/min flow) used in this study. It can be concluded, that with this modern HFA drug formulation, the deposition is high, even in obstructed lungs...
  91. ncbi Effect of formoterol with or without budesonide in repeated low-dose allergen challenge
    B Dahlen
    Division of Respiratory Medicine and Allergy, Dept of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Eur Respir J 33:747-53. 2009
    ..Signs of deteriorating asthma, provoked by low-dose allergen, are prevented by short-term use of budesonide/formoterol but not by temporary use of formoterol alone...
  92. pmc Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen
    Hendrik Jan de Heer
    Department of Pulmonary Medicine, Erasmus Medical Center, Dr Molewaterplein 50, 3015 GE Rotterdam, Netherlands
    J Exp Med 200:89-98. 2004
    ..These studies show that pDCs provide intrinsic protection against inflammatory responses to harmless antigen. Therapies exploiting pDC function might be clinically effective in preventing the development of asthma...
  93. ncbi Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease
    Donald A Mahler
    Dartmouth Hitchcock Medical Center, Section of Pulmonary and Critical Care Medicine, 1 Medical Center Drive, Lebanon, NH 03756 0001, USA
    Am J Respir Crit Care Med 166:1084-91. 2002
    ..We conclude that FSC improved lung function and reduced the severity of dyspnea compared with individual components and placebo...
  94. ncbi The CFC to HFA transition and its impact on pulmonary drug development
    Chet L Leach
    Lovelace Respiratory Research Institute, Albuquerque, New Mexico 87108, USA
    Respir Care 50:1201-8. 2005
    ..The transition from CFCs also spurred novel new drug-delivery technologies, improved dry powder inhalers, and highly dispersible engineered powders...
  95. ncbi Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma: protection by inhaled steroids
    Josephine de Kluijver
    Department of Pulmonology, Lung Function Laboratory, C2 P 62 Leiden University Medical Center, PO Box 9600, NL 2300 RC Leiden, The Netherlands
    Am J Respir Crit Care Med 166:294-300. 2002
    ..This suggests that antiinflammatory therapy is beneficial during allergen exposure, even during asymptomatic episodes...
  96. ncbi Exaggerated airway narrowing in mice treated with intratracheal cationic protein
    Jason H T Bates
    Vermont Lung Center, University of Vermont College of Medicine, Burlington, VT 05405 0075, USA
    J Appl Physiol (1985) 100:500-6. 2006
    ....
  97. ncbi Inhaling medicines: delivering drugs to the body through the lungs
    John S Patton
    Nektar Therapeutics, 150 Industrial Road, San Carlos, California 94070, USA
    Nat Rev Drug Discov 6:67-74. 2007
    ..Here, we review these advances, and discuss aspects of lung physiology and formulation composition that influence the systemic delivery of inhaled therapeutics...
  98. ncbi Regulation of dendritic cell recruitment into resting and inflamed airway epithelium: use of alternative chemokine receptors as a function of inducing stimulus
    P A Stumbles
    TVW Telethon Institute for Child Health Research, and Centre for Child Health Research, University of Western Australia, Perth, Western Australia, Australia
    J Immunol 167:228-34. 2001
    ....
  99. ncbi A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis
    Mark R Elkins
    Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia
    N Engl J Med 354:229-40. 2006
    ..Inhaled hypertonic saline acutely increases mucociliary clearance and, in short-term trials, improves lung function in people with cystic fibrosis. We tested the safety and efficacy of inhaled hypertonic saline in a long-term trial...
  100. ncbi Budesonide reduces sensitivity and reactivity to inhaled mannitol in asthmatic subjects
    John D Brannan
    Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Respirology 7:37-44. 2002
    ..The aim of the study was to investigate whether treatment using inhaled corticosteroids decreases airway responsiveness to inhaled mannitol in asthmatic subjects...
  101. ncbi Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations
    J Matz
    Atlantic Asthma and Allergy Center, Inc, Baltimore, MD, USA
    J Allergy Clin Immunol 107:783-9. 2001
    ..The ability to detect deteriorating asthma and the severity of exacerbation was similar between groups...

Research Grants76

  1. Influenza therapy by Au-nanorod 5'PPP-NS1-siRNA/cDNA targeting of bronchial cells
    Paul R Knight; Fiscal Year: 2010
    ..well suited for these treatment strategies as direct contact with the environment provides a portal for inhalation administration of cDNA and siRNA conjugated nanoplexes...
  2. Quantitative MRI-based Assessment of Aerosol Deposition in the Lung
    Chantal Darquenne; Fiscal Year: 2009
    ..The technique developed in the proposed research will also enable future MRI studies of numerous different lung disease models. ..
  3. Inhalable amphotericin B nanodisk therapy for pulmonary aspergillosis
    Trudy Forte; Fiscal Year: 2005
    ..fumigatus infection. We will examine the overall suitability of ND-AMB for inhalation administration, specifically, ND-AMB compatibility with inhaleable dry powder synthesis and the ability of ND-AMB to ..
  4. TOXICITY AND CARCINOGENICITY TESTS OF ACETONITRILE
    HARVEY RAGAN; Fiscal Year: 1992
    ..The results of the 2-year chronic study will be used by NTP to determine toxicologic and carcinogenic effects of inhalation administration of acetonitrile.
  5. INHALED NO FOR THE PREVENTION OF CHRONIC LUNG DISEASE
    John Kinsella; Fiscal Year: 2004
    ..This study design also allows for insights into the role of inflammatory markers in prediction of CLD risk in the premature newborn. ..
  6. Aerosolized PGE1 in Neonatal Pulmonary Hypertension
    BEENA SOOD; Fiscal Year: 2005
    ..If effective, a proposal for using aerosolized PGE1 in neonatal PPHN as a multicenter study will be submitted to the NICHD Neonatal Network. ..
  7. Self-administration of abused inhalants in mice
    Scott Bowen; Fiscal Year: 2004
    ....
  8. Behavioral Effects of Gestational Inhalant Abuse in Rats
    Scott Bowen; Fiscal Year: 2006
    ..Finally, this research has the potential to assist in the design of effective treatments for inhalant abuse. [unreadable] [unreadable]..
  9. A Preclinical Model of Adolescent Toluene Abuse in Rats
    Scott Bowen; Fiscal Year: 2005
    ..The model also has the potential to assist in devising effective treatments and prevention strategies for adolescent inhalant abuse. ..
  10. CALORIC RESTRICTION, AGING, AND INSULIN ACTION
    William Cefalu; Fiscal Year: 2001
    ....
  11. USING INFORMATION TECHNOLOGY TO IMPROVE ASTHMA ADHERENCE
    Keoki Williams; Fiscal Year: 2008
    ..abstract_text> ..
  12. MECHANISMS OF RESPONSE TO PULMONARY VACCINATION
    Anthony Hickey; Fiscal Year: 2005
    ..The significance of this work lies in the novelty of pulmonary vaccination for the treatment of tuberculosis and the knowledge of the immune response gained from targeted antigen delivery to the lungs. ..
  13. Mechanism of Endotoxin's Effect On Allergy Risk
    Keoki Williams; Fiscal Year: 2008
    ..It is the hoped that understanding the mechanism of endotoxin's effect will establish new targets for the prevention of allergies. ..
  14. CONTROL OF IGE MEDIATED PULMONARY INFLAMMATION IN HUMANS
    Stephen Peters; Fiscal Year: 2001
    ....
  15. TLR's, Nitric Oxide and Chronic Lung Disease
    William Truog; Fiscal Year: 2005
    ..Its results may also open up intriguing pathways for treatments aimed at selective diminution of pulmonary inflammation. ..
  16. Chromium, Cellular Energy Status and Whole Body Energy Balance
    William Cefalu; Fiscal Year: 2007
    ..abstract_text> ..
  17. ASTHMA CLINICAL RESEARCH NETWORK (ACRN)
    Stephen Peters; Fiscal Year: 2007
    ....
  18. THE CLINICAL EFFECTIVENESS OF PHARMACY ADHERENCE INFORMATION FOR DIABETES CONTROL
    Keoki Williams; Fiscal Year: 2010
    ..Analyses will control for cluster randomization effects. The introduction of sustainable medication adherence monitoring in clinical practice holds great potential to improve health outcomes among patients with diabetes. ..
  19. HORMONE REPLACEMENT FOR PREVENTION OF VISCERAL OBESITY
    William Cefalu; Fiscal Year: 2002
    ....
  20. Chromium and Insulin Action
    William Cefalu; Fiscal Year: 2006
    ..abstract_text> ..
  21. A COLLABORATIVE GENOMIC STUDY OF BIPOLAR DISORDER
    William Coryell; Fiscal Year: 2007
    ..Analysis of the existing sib pair families plus this large set of cases and controls should permit the confirmation of several vulnerability genes during this grant period. ..
  22. Temporal Integration in Nasal Lateralization
    Paul Wise; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  23. VEGF and Nitric Oxide in Lung Vascular Development
    Vivek Balasubramaniam; Fiscal Year: 2007
    ..In addition, Dr. Balasubramaniam will continue to work with Dr. Charles Plopper (UC Davis) to learn more sophisticated techniques of morphometric analysis. ..
  24. Treatment of Severe Persistent Asthma
    ROBERT LEMANSKE; Fiscal Year: 2007
    ..abstract_text> ..
  25. Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children
    Carlos Camargo; Fiscal Year: 2008
    ..The proposed study is cost-effective, as it makes use of an existing cohort, and it will provide information that could have direct clinical application to reduce risk of asthma. [unreadable] [unreadable] [unreadable] [unreadable]..
  26. Genetics of Early-Onset Depression
    William Coryell; Fiscal Year: 2008
    ..abstract_text> ..
  27. COLLABORATIVE DEPRESSION STUDY
    William Coryell; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  28. MECHANICS OF ACUTE LUNG INJURY
    Jason Bates; Fiscal Year: 2009
    ..The results of our studies are expected to lead to the design of physiologically-based lung recruitment strategies that can be tailored to the individual patient with ALI. This will set the stage for future clinical trials. ..
  29. Assessment of Lung function in Mice
    Jason Bates; Fiscal Year: 2009
    ....
  30. Monitoring transplant kidney function with MRI
    SEAN BEDILION FAIN; Fiscal Year: 2010
    ....
  31. Pediatric Severe Asthma: Role of Oxidant Stress and Alveolar Macrophage Function
    Anne Fitzpatrick; Fiscal Year: 2009
    ..This proposal will lay the foundation for further studies, and the mechanisms identified may ultimately be targeted in future interventional trials. ..
  32. Regulation and role of CEACAM6 in the lung alveolus
    Philip L Ballard; Fiscal Year: 2011
    ..The studies of this project will examine expression and function of the protein in normal lung and its role in response to lung injury and infection. ..
  33. Prospective Study of Diet, Physical Activity, BMI and Risk of Pulmonary Embolism
    Carlos Camargo; Fiscal Year: 2008
    ..We believe that quantifying these modifiable risk factors will lead to public health interventions that decrease the incidence of pulmonary embolism in the elderly population. [unreadable] [unreadable] [unreadable]..
  34. Response to Beta2-Agonists in Acute Severe Asthma
    Nicola Hanania; Fiscal Year: 2008
    ..abstract_text> ..
  35. Distal Lung Inflammation Effect on Asthma Exacerbations
    Donald Tashkin; Fiscal Year: 2008
    ..This study has the potential to clarify the contribution of the "silent zone" to the persistent morbidity encountered with asthma. ..
  36. Marijuana use patterns: Temporal change in predictors, perceptions, and ad impact
    WILLIAM CRANO; Fiscal Year: 2008
    ..abstract_text> ..
  37. CARE Network - Madison Clinical Center
    ROBERT LEMANSKE; Fiscal Year: 2008
    ..abstract_text> ..
  38. Childhood Asthma Research and Education Network: Denver Site
    Stanley Szefler; Fiscal Year: 2008
    ..End of abstract.) [unreadable] [unreadable]..
  39. Effectiveness of the TB Contact Priority Model
    William Bailey; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  40. Obesity, Inflammation and Response to Therapy in Asthma
    EVERETT RAND SUTHERLAND; Fiscal Year: 2010
    ..End of Abstract) ..
  41. Development of Therapeutic Inhibitors to Anthrax Toxins
    JOHNNY PETERSON; Fiscal Year: 2006
    ..anthracis, increase the efficacy of antibiotics, promote killing of the bacteria by phagocytes, and enhance vaccine-induced immunity. [unreadable] [unreadable]..
  42. ASTHMA CLINICAL RESEARCH NETWORK
    ROBERT LEMANSKE; Fiscal Year: 2002
    ....
  43. Determinants of Tolerance to Nitrous Oxide Hypothermia
    Karl Kaiyala; Fiscal Year: 2004
    ..These studies have theoretical importance for understanding the mechanisms of drug tolerance and will begin to suggest the physiological basis of individual differences in vulnerability to addiction and drug abuse. ..
  44. ASSESSMENT MODE AND VALIDITY OF SELF-REPORTS IN CHILDREN
    Bruce Bender; Fiscal Year: 2004
    ..Results from this investigation are expected to have immediate and direct implication for clinical research in asthma and with other chronic conditions. ..
  45. TRAIT MARKER FOR PANIC DISORDER
    William Coryell; Fiscal Year: 2001
    ..If the study's predictions are sustained, subsequent efforts will be directed toward lengthening the follow-up period and toward an eventual, ten-year diagnostic reassessment. ..
  46. SCLERODERMA LUNG STUDY
    Donald Tashkin; Fiscal Year: 2003
    ..abstract_text> ..
  47. GAS EXCHA03NGE IMAGING IN THE LUNG USING MRI
    Samuel Patz; Fiscal Year: 2001
    ..Early detection of the loss of alveolar surface area is a serious public health imperative, since chronic obstructive pulmonary disease is now the Th leading cause of death in the US. ..
  48. Adherence & Treatment Outcome in Adolescents in CAMPCS
    Bruce Bender; Fiscal Year: 2003
    ..abstract_text> ..
  49. PREOPERATIVE TREATMENT OF LUNG CANCER WITH rhuMab VEGF
    Gregory Otterson; Fiscal Year: 2003
    ..Careful comparison/analysis of clinical and biologic information gathered in this study will likely enhance our understanding of tumor growth and progression as well as response to therapy. ..
  50. DIET AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Carlos Camargo; Fiscal Year: 2002
    ..The proposed study is cost-effective, as it makes use of an existing cohort, and it will provide information that could have direct clinical application to reduce risk of COPD. ..
  51. LUNG HEALTH STUDY--LONG TERM FOLLOW UP
    Donald Tashkin; Fiscal Year: 2002
    ..All ten of the original LHS clinical centers plan to participate in this study. To minimize bias, all surviving participants of the LHS will be invited to participate, giving a potential sample size of 5600. ..
  52. ROLE OF ENDOTHELIN IN PERINATAL PULMONARY VASOREGULATION
    DAVID IVY; Fiscal Year: 2002
    ..Research presentations along with graduate level courses in molecular biology, and the clinical ambiance of the Univ of CO SOM in the area of pulmonary hypertension enhance career development. ..
  53. CYTOKINE DYSREGULATION, VIRUSES, AND CHILDHOOD ASTHMA
    ROBERT LEMANSKE; Fiscal Year: 2001
    ..The results of these studies will provide information that will be a major step forward in our understanding of the relative influence that genetic and environmental risk factors on the development of childhood asthma. ..
  54. Infrastructure and Applications of Hyperpolarized 129Xe
    Samuel Patz; Fiscal Year: 2006
    ..A polarizer will be built, sited and supported at Brigham and Women's Hospital. Animal and human studies are proposed to demonstrate the structural and functional information 129Xe MRI can provide. ..
  55. Reducing Inhalant Use in Young Adolescents
    WILLIAM CRANO; Fiscal Year: 2005
    ..It is hypothesized that messages focusing on social identity will be most effective in this population--especially if delivered by a peer source. ..
  56. IMMUNE MECHANISMS OF MIDDLE EAR DISEASE
    David Skoner; Fiscal Year: 2006
    ..The primary hypothesis is that cytokine genotype is predictive of illness expression and of OM incidence during a documented RSV infection in young children. ..
  57. Neuroadaptive Substrates for Nitrous Oxide Tolerance
    Karl Kaiyala; Fiscal Year: 2006
    ..This work will be the first to identify brain areas activated by a drug-induced hypothermic stimulus and its adaptive consequences. These studies have theoretical importance for understanding and treating drug addiction. ..
  58. New Mechanisms in the Pathogenesis of Cholera
    JOHNNY PETERSON; Fiscal Year: 2006
    ..Although CTs action is a multifaceted mechanism, therapeutic control of CT- induced hypersecretion of water and electrolytes in cholera may be possible by modulating AA metabolism. ..
  59. CONFERENCE ON PARTICULATE AIR POLLUTION AND HUMAN HEALTH
    Robert Phalen; Fiscal Year: 2003
    ..To add significantly to the peer-reviewed literature by publishing research results presented at the conference in a variety of special issues of selected journals. ..
  60. Computerized ASI Follow-up and Outcome System
    Stephen Butler; Fiscal Year: 2004
    ..Client acceptance will be evaluated along with correspondence between the IVR and traditional ASI administration. Phase II will evaluate the system's validity, capacity to produce acceptable response rates, and cost-effectiveness. ..
  61. ASI-MV.net: A Prescription Medication Monitoring Tool
    Stephen Butler; Fiscal Year: 2006
    ..Phase II will fully develop the ASI-MV.net website and establish its reliability and validity. The ASI-MV.net will be an innovative solution to problems collecting product-specific addictions data in real time. [unreadable] [unreadable]..
  62. EXPERIMENTAL TESTING OF THE DESIGNATED DRIVER CONCEPT
    James Lange; Fiscal Year: 2003
    ..Further, the methods used will recruit whole groups, so that these trials will offer an opportunity to study the effects of a designated driver on the results of passengers' BACs. ..
  63. A Chinese Adaptation of the ASI-Multimedia Version
    Stephen Butler; Fiscal Year: 2004
    ..The final product will be marketed as part of our extensive suite of substance abuse-related, multimedia tools. ..
  64. Internet Monitoring Of Prescription Drug Abuse
    Stephen Butler; Fiscal Year: 2006
    ..Phase II will see development of a full prototype of PRISM and demonstration of its reliability and internal and external validity. [unreadable] [unreadable] [unreadable] [unreadable]..
  65. SCHOOL BASED DRUG PREVENTION PROGRAM
    Christopher Ringwalt; Fiscal Year: 2001
    ....
  66. COMMUNITY PARTNERSHIP TO REDUCE ASTHMA DISPARITIES
    Elizabeth McQuaid; Fiscal Year: 2009
    ..A Sustainability Advisory board will provide guidance regarding project implementation in the community beyond the life of the grant. ..
  67. MECHANISMS REGULATING AIRWAY MUSCLE GROWTH
    Reynold Panettieri; Fiscal Year: 2003
    ..These studies will define the mechanism by which agonists induce ASM cell growth such that new issues in the pathogenesis of asthma will be addressed and therapeutic measures to prevent these alterations can be developed. ..
  68. Mechanisms of VEGF modulation of smooth muscle function
    Reynold Panettieri; Fiscal Year: 2009
    ..abstract_text> ..
  69. Ozone ALTERS Airway Smooth Muscle FUNCTION IN ASTHMA
    Reynold Panettieri; Fiscal Year: 2008
    ..These studies will identify the mechanisms by which ozone enhances allergen-induced AHR and provide insight into new therapeutic targets to prevent asthma exacerbations and decrease asthma morbidity and mortality. ..
  70. MECHANISMS OF SMOOTH MUSCLE HYPERREACTIVITY ON ASTHMA
    Prescott Woodruff; Fiscal Year: 2006
    ..The candidate will complement these studies with a curriculum of advanced training in methods for the design and analysis of gene expression studies in human subjects. ..
  71. Mechanisms Regulation Functions of Airway Smooth Muscle
    Reynold Panettieri; Fiscal Year: 2007
    ..Thus, understanding the transcriptional mechanisms regulating the expression of inflammatory genes in ASM will likely lead to new therapeutic approaches for the treatment of asthma. ..
  72. TESTING INTERVENTIONS IN PEDIATRIC ASTHMA
    Elizabeth McQuaid; Fiscal Year: 2002
    ..Exploratory analyses will investigate mediators of behavior change. Results will be used to design a larger, randomized controlled trial comparing behavioral feedback to asthma education. ..
  73. T CELL INFLAMMATION AND MUCIN HYPERSECRETION IN COPD
    John Fahy; Fiscal Year: 2004
    ..abstract_text> ..
  74. Promoting Fidelity Using Remote and Onsite Support
    Christopher Ringwalt; Fiscal Year: 2006
    ..Study results will inform the prevention field concerning the potential for personalized coaching and technical assistance to promote curriculum fidelity and affect key student-level mediating variables. ..